Prior diagnoses and therapies for patients with t-ALL or pm-ALL
| Characteristics . | t-ALL . | pm-ALL . |
|---|---|---|
| Type of prior malignancy | ||
| Breast cancer | 31 (26) | 6 (30) |
| Multiple myeloma | 22 (19) | 1 (5) |
| Prostate cancer | 15 (13) | 4 (20) |
| Non-Hodgkin lymphoma | 13 (11) | 0 (0) |
| Hodgkin lymphoma | 6 (5) | 0 (0) |
| Thyroid cancer | 5 (4) | 0 (0) |
| Colorectal carcinoma | 4 (3.4) | 0 (0) |
| Cervical cancer | 4 (3.4) | 1 (5) |
| Lung cancer | 3 (2.6) | 1 (5) |
| Testicular cancer | 3 (2.6) | 0 (0) |
| Sarcoma | 2 (1.7) | 0 (0) |
| Chronic lymphocytic leukemia | 2 (1.7) | 1 (5) |
| Head and neck cancer | 2 (1.7) | 1 (5) |
| Bladder cancer | 2 (1.7) | 0 (0) |
| Langerhans cell histiocytosis | 1 (0.8) | 0 (0) |
| Anal carcinoma | 1 (0.8) | 0 (0) |
| Brain cancer | 1 (0.8) | 0 (0) |
| Ovarian cancer | 1 (0.8) | 0 (0) |
| Hepatocellular carcinoma | 1 (0.8) | 0 (0) |
| Melanoma | 0 (0) | 5 (25) |
| More than 1 previous malignancy | 7 (6) | 3 (15) |
| Type of prior therapy | n/a | |
| Alkylating agents | 71 (62.3) | |
| Topoisomerase II inhibitors | 37 (32.4) | |
| Alkylating agent + topoisomerase II inhibitor | 34 (29.8) | |
| Other chemotherapy | 11 (9.6) | |
| Radiotherapy | 64 (56.1) | |
| Chemoradiotherapy | 40 (35.1) |
| Characteristics . | t-ALL . | pm-ALL . |
|---|---|---|
| Type of prior malignancy | ||
| Breast cancer | 31 (26) | 6 (30) |
| Multiple myeloma | 22 (19) | 1 (5) |
| Prostate cancer | 15 (13) | 4 (20) |
| Non-Hodgkin lymphoma | 13 (11) | 0 (0) |
| Hodgkin lymphoma | 6 (5) | 0 (0) |
| Thyroid cancer | 5 (4) | 0 (0) |
| Colorectal carcinoma | 4 (3.4) | 0 (0) |
| Cervical cancer | 4 (3.4) | 1 (5) |
| Lung cancer | 3 (2.6) | 1 (5) |
| Testicular cancer | 3 (2.6) | 0 (0) |
| Sarcoma | 2 (1.7) | 0 (0) |
| Chronic lymphocytic leukemia | 2 (1.7) | 1 (5) |
| Head and neck cancer | 2 (1.7) | 1 (5) |
| Bladder cancer | 2 (1.7) | 0 (0) |
| Langerhans cell histiocytosis | 1 (0.8) | 0 (0) |
| Anal carcinoma | 1 (0.8) | 0 (0) |
| Brain cancer | 1 (0.8) | 0 (0) |
| Ovarian cancer | 1 (0.8) | 0 (0) |
| Hepatocellular carcinoma | 1 (0.8) | 0 (0) |
| Melanoma | 0 (0) | 5 (25) |
| More than 1 previous malignancy | 7 (6) | 3 (15) |
| Type of prior therapy | n/a | |
| Alkylating agents | 71 (62.3) | |
| Topoisomerase II inhibitors | 37 (32.4) | |
| Alkylating agent + topoisomerase II inhibitor | 34 (29.8) | |
| Other chemotherapy | 11 (9.6) | |
| Radiotherapy | 64 (56.1) | |
| Chemoradiotherapy | 40 (35.1) |
All data are n (%).